Dual Stimuli-Responsive Peptide-Based Palladium Nano-Lychee Spheres for Synergistic Antitumor Therapy
Source abstract
Abstract
The application of peptide-based biomaterials in nanocarriers can effectively reduce toxicity and improve the biocompatibility. In our study, a dual stimuli-responsive peptide-based drug delivery system was designed and synthesized, which was nontoxic and achieved the chem-photothermal therapy synergistic effect. Lanreotide (Lan), a kind of somatostatin analogue, was used as internal template to prepared lychee-shaped palladium (Pd) nanoparticles (Lan-PdNPs). Glutathione (GSH) and doxorubicin (DOX) were combined on the surface of Lan-PdNPs to obtain the nanosystem of Lan-PdNPs@GSH/DOX. Based on the lychee-shaped structures, the system demonstrated higher photothermal conversion performance and photothermal stability. Under NIR laser irradiation, Lan-PdNPs@GSH/DOX could convert light energy to heat in effect and accelerate drug release. Moreover, in acidic conditions, the system also exhibited the pH-responsive drug release. Owing to the synergism, the antitumor effects of Lan-PdNPs@GSH/DOX in vitro and in vivo were superior, and the inhibition ratio was much higher than that of chemotherapy or photothermal therapy alone. The good biocompatibility and nontoxicity of the system also provide the possibility for serving as an antitumor drug candidate.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Applying Chemistry Key Lab of Hebei Province, Department of Bioengineer, Yanshan University, No. 438 Hebei Street, Qinhuangdao 066004, P. R. China
State Key Laboratory of Metastable Materials Science and Technology, Yanshan University, Qinhuangdao 066004, P. R. China
Hebei Province Asparagus Industry Technology Research Institute, Qinhuangdao 066004, P. R. China
Funding
Department of Education of Hebei Province · National Natural Science Foundation of China · Hebei Province
References (51)
Show source-provided references
1. 10.1002/adhm.20180100210.1002/adhm.201801002 ↗
2. 10.1039/c5sc04392a10.1039/c5sc04392a ↗
3. 10.1021/acsami.7b1813710.1021/acsami.7b18137 ↗
4. 10.1002/advs.20170099110.1002/advs.201700991 ↗
5. 10.1016/j.biomaterials.2018.09.03910.1016/j.biomaterials.2018.09.039 ↗
6. 10.1016/j.nano.2018.04.01810.1016/j.nano.2018.04.018 ↗
7. 10.1016/j.nano.2018.09.00810.1016/j.nano.2018.09.008 ↗
8. 10.1016/j.nano.2018.09.01510.1016/j.nano.2018.09.015 ↗
9. 10.1039/c9nj01101c10.1039/c9nj01101c ↗
10. 10.1039/c8cc08445a10.1039/c8cc08445a ↗
11. 10.1039/c6nr07315h10.1039/c6nr07315h ↗
12. 10.1038/s41467-017-01565-610.1038/s41467-017-01565-6 ↗
13. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
14. 10.1002/adfm.20180449210.1002/adfm.201804492 ↗
15. 10.2174/156802661566615060512045610.2174/1568026615666150605120456 ↗
16. 10.1021/acssuschemeng.8b0041510.1021/acssuschemeng.8b00415 ↗
17. 10.1039/C7TB01146F10.1039/C7TB01146F ↗
18. 10.2217/nnm-2018-006710.2217/nnm-2018-0067 ↗
19. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
20. 10.1016/j.pmatsci.2018.07.00510.1016/j.pmatsci.2018.07.005 ↗
21. Urano M. · Cancer Res · 1986 · 46 · 474
22. 10.1016/j.nano.2016.05.01310.1016/j.nano.2016.05.013 ↗
23. 10.1002/smll.20180360210.1002/smll.201803602 ↗
24. 10.1002/adfm.20180558210.1002/adfm.201805582 ↗
25. 10.1002/psc.91310.1002/psc.913 ↗
26. 10.1088/1742-6596/687/1/01211210.1088/1742-6596/687/1/012112 ↗
27. 10.1021/bi010232q10.1021/bi010232q ↗
28. 10.1021/ja003381p10.1021/ja003381p ↗
29. 10.1038/nmat191210.1038/nmat1912 ↗
30. 10.1021/jp111907410.1021/jp1119074 ↗
31. 10.1007/s11051-011-0449-110.1007/s11051-011-0449-1 ↗
32. 10.1002/smll.20150396110.1002/smll.201503961 ↗
33. 10.1021/nl062969c10.1021/nl062969c ↗
34. 10.1021/jacs.5b0532110.1021/jacs.5b05321 ↗
35. 10.1021/acs.nanolett.8b0293310.1021/acs.nanolett.8b02933 ↗
36. 10.1039/c5tc00246j10.1039/c5tc00246j ↗
37. 10.1021/acs.molpharmaceut.6b0073810.1021/acs.molpharmaceut.6b00738 ↗
38. 10.1016/j.jconrel.2018.05.00210.1016/j.jconrel.2018.05.002 ↗
39. 10.1039/c1nr10969c10.1039/c1nr10969c ↗
40. 10.1021/la204831b10.1021/la204831b ↗
41. 10.1021/acsami.5b0266610.1021/acsami.5b02666 ↗
42. 10.1002/adma.20120468310.1002/adma.201204683 ↗
43. 10.1021/nl201400z10.1021/nl201400z ↗
44. 10.1002/adfm.20170736010.1002/adfm.201707360 ↗
45. 10.1007/s12274-017-1736-710.1007/s12274-017-1736-7 ↗
46. 10.1039/C5NR07773G10.1039/C5NR07773G ↗
47. 10.1016/j.ijbiomac.2016.06.00710.1016/j.ijbiomac.2016.06.007 ↗
48. 10.1021/acsami.6b0096310.1021/acsami.6b00963 ↗
49. 10.1039/C7TB03325G10.1039/C7TB03325G ↗
50. 10.1002/adfm.20170682710.1002/adfm.201706827 ↗
51. 10.1021/acsami.7b0839810.1021/acsami.7b08398 ↗